Enliven Therapeutics Appoints Kristine Ball to Board of Directors Ahead of Planned Phase 3 Trial Initiation this YearPRNewsWire · Oct 14, 2026
Enliven Therapeutics Announces FDA Alignment on ENABLE-2 Phase 3 Trial Design for Relcobatinib (ELVN-001) in Previously Treated Chronic Myeloid LeukemiaPRNewsWire · Oct 6, 2026
Enliven Therapeutics (NASDAQ:ELVN) Stock Falls 4.5% Following Insider SellingDefense World · Oct 6, 2026
This Enliven Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For FridayBenzinga · Oct 2, 2026
Enliven Therapeutics, Inc. (ELVN) Presents at Morgan Stanley 24th Annual Global Healthcare Conference TranscriptSeeking Alpha · Sep 16, 2026
Enliven Therapeutics to Present at Upcoming Investor ConferencesPRNewsWire · Sep 3, 2026Enliven Therapeutics, Inc. is a biopharmaceutical enterprise, currently in the clinical development phase, dedicated to discovering and advancing small molecule therapeutic agents aimed at combating cancer. Its pipeline includes ELVN-001, a small molecule kinase inhibitor currently in a Phase 1 clinical trial for adult patients with chronic myeloid leukemia. Another key candidate, ELVN-002, also a small molecule kinase inhibitor, has begun a Phase 1 clinical assessment for individuals with cancers exhibiting an abnormal HER2 gene.
| Date | Est. | Actual | |
|---|---|---|---|
| Aug 5, 2026 | -$0.39 | -$0.49 | Miss |
| May 7, 2026 | -$0.44 | -$0.38 | Beat |
| Mar 3, 2026 | -$0.42 | -$0.48 | Miss |
| Nov 12, 2025 | -$0.43 | -$0.32 | Beat |
| Aug 13, 2025 | -$0.53 | -$0.49 | Beat |
| May 14, 2025 | -$0.51 | -$0.57 | Miss |